Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

516.74 +14.29 (+2.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
53 54 Next >
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Vertex Pharmaceuticals: Buy, Sell, or Hold?
The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? 
Via The Motley Fool
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to... 
Via Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons 
Via Benzinga
Topics Economy
Exposures Interest Rates
1 Top Growth Stock to Buy and Hold Forever
This drugmaker looks unstoppable. 
Via The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today
Via Benzinga
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
The companies expect the deal to close later this quarter. 
Via Investor's Business Daily
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?
This innovative machine rolls on. 
Via The Motley Fool
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over 
Via Benzinga
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term. 
Via InvestorPlace
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
These companies are close to launching new products that could supercharge revenue. 
Via The Motley Fool
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
These businesses are booming. 
Via The Motley Fool
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
All three companies have very long runways for growth ahead. 
Via The Motley Fool
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years
Great businesses are here to stay. These are two excellent examples. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. 
Via InvestorPlace
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease”
Via AB Newswire
Exposures Product Safety
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Biopharma Stocks Predicted to Soar in Q2 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals. 
Via InvestorPlace
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
Via InvestorPlace
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
It's always a good time to buy great stocks with excellent prospects. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.